| Literature DB >> 16282947 |
Donald Null1, Bernard Pollara, Penelope H Dennehy, Jean Steichen, Pablo J Sánchez, Laurence B Givner, David Carlin, Bernard Landry, Franklin H Top, Edward Connor.
Abstract
To evaluate the safety and immunogenicity of palivizumab, 55 children who received palivizumab in the IMpact-RSV trial received 5 monthly doses of 15 mg/kg palivizumab (Synagis) during the subsequent year. The single child with an antipalivizumab titer of >1/40 had no associated serious adverse events and had expected serum palivizumab trough concentrations. Second year palivizumab prophylaxis was safe and well-tolerated.Entities:
Mesh：
Substances：
Year: 2005 PMID： 16282947 DOI： 10.1097/01.inf.0000183938.33484.bd
Source DB: PubMed Journal: Pediatr Infect Dis J ISSN： 0891-3668 Impact factor: 2.129